Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.30 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3601324 | 0.81 | CHRNB2 (0.36) | KDM4ECHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL9678381 | 0.81 | LMNA (0.31) | KDM4ECHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL17623531 | 0.79 | CHRNB2 (0.31) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL16177930 | 0.78 | — | — | |
| SCHEMBL16177928 | 0.78 | — | — | |
| SCHEMBL475660 | 0.72 | CYP1A2 (0.33) | KDM4ECYP1A2HIF1A | |
| SCHEMBL14649971 | 0.72 | CYP1A2 (0.33) | KDM4ECYP1A2HIF1A | |
| SCHEMBL475658 | 0.72 | CYP1A2 (0.33) | KDM4ECYP1A2HIF1A | |
| SCHEMBL24664101 | 0.68 | CYP1A2 (0.33) | KDM4ECYP1A2HIF1A | |
| SCHEMBL19386329 | 0.68 | CYP1A2 (0.33) | CYP1A2HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8598346-B2 | Synthesis of cyclic amidines | BITOP AG (DE) | 2013-12-03 | — | — | US | disclosed |
| US-20110178292-A1 | SYNTHESIS OF CYCLIC AMIDINES | BITOP AG (DE) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178292-A1 | SYNTHESIS OF CYCLIC AMIDINES | ODC1, PAM, COASY | KDM4E 3917/4885KCNMA1 3891/4885CHRNB2 3017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.